639090-53-2

Basic information

• Product Name: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide
• Synonyms: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide;N-(4-(4,6-dichloropyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide;N-[4-[(4,6-Dichloro-2-pyrimidinyl)thio]phenyl]cyclopropanecarboxamide;N-{4-[(4,6-dichloropyriMidin-2-yl)sulfanyl]phenyl}cyclopropanecarboxaMide;cyclopropane carboxylic acid [4-(4,6-dichloro-pyriMidin-2-ylsulphanyl)-phenyI]-aMide
• CAS NO: 639090-53-2
• Molecular Formula: C₁₄H₁₁Cl₂N₃OS
• Molecular Weight: 340.23
• Product Categories: API intermediates
• Mol File: 639090-53-2.mol

Chemical Properties

• Appearance: /
• Density: 1.52
• Refractive Index: 1.684
• CAS DataBase Reference: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(639090-53-2)
• EPA Substance Registry System: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(639090-53-2)

Safety Data

• Hazardous Substances Data: 639090-53-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide is used as a potential therapeutic agent for the treatment of certain diseases due to its inhibitory activity against specific enzymes. Its unique chemical structure and biological properties make it a promising candidate for further research and development in the field of medicine.
Further exploration of Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide's properties and mechanisms of action may lead to its eventual use as a therapeutic agent, offering new treatment options for patients suffering from various conditions. The development of novel drug delivery systems and formulations may also enhance the bioavailability, efficacy, and safety of Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide, expanding its potential applications in the pharmaceutical industry.

InChI:InChI=1/C14H11Cl2N3OS/c15-11-7-12(16)19-14(18-11)21-10-5-3-9(4-6-10)17-13(20)8-1-2-8/h3-8H,1-2H2,(H,17,20)

Upstream product

• 639090-54-3 (N-(4-mercaptophenyl)cyclopropylcarboxamide) 
• 4489-34-3 4,6-dichloro-2-(methylsulfonyl)pyrimidine 
• 1193-02-8 4-aminotiophenol 

Downstream Products

• 639090-55-4 N-[4-({4-chloro-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropane carboxamide 
• 1079394-26-5 N-(4-(4-(1,2,4-thiadiazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-27-6 N-(4-(4-chloro-6-(pyridin-2-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1170188-57-4 N-(4-(4-(2-aminoethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1450754-47-8 N-(4-(4-(2-(3-(but-3-ynyl)-3H-diazirin-3-yl)ethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-18-5 N-(4-(4-(3-cyclopropyl-3-fluoroazetidin-1-yl)-6-(pyridin-2-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-17-4 N-(4-(4-(1,2,4-thiadiazol-5-ylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 639090-55-4 N-(4-((4-chloro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)thio)phenyl)cyclopropanecarboxamide 

Relevant articles and documents

PYRIMIDINE DERIVATIVES AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present invention relates to novel TrkA inhibitors ofofmrula (1) which are useful in the treatment or prevention of acute and chronic pain but also for other abnormal activities of TrkA beyond pain therapy, such as inflammation and cancer.

From Cancer to Pain Target by Automated Selectivity Inversion of a Clinical Candidate

Elimination of inadvertent binding is crucial for inhibitor design targeting conserved protein classes like kinases. Compounds in clinical trials provide a rich source for initiating drug design efforts by exploiting such secondary binding events. Considering both aspects, we shifted the selectivity of tozasertib, originally developed against AurA as cancer target, toward the pain target TrkA. First, selectivity-determining features in binding pockets were identified by fusing interaction grids of several key and off-target conformations. A focused library was subsequently created and prioritized using a multiobjective selection scheme that filters for selective and highly active compounds based on orthogonal methods grounded in computational chemistry and machine learning. Eighteen high-ranking compounds were synthesized and experimentally tested. The top-ranked compound has 10000-fold improved selectivity versus AurA, nanomolar cellular activity, and is highly selective in a kinase panel. This was achieved in a single round of automated in silico optimization, highlighting the power of recent advances in computer-aided drug design to automate design and selection processes.

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

As inhibitors of Aurora kinases substituted pyrimidine derivatives

The present invention relates to a substituted and aurora kinase-inhibiting pyrimidine derivative as represented by formula (I) or (Ia), tautomer, hydrate, solvate, ester or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the compounds as active ingredients, as well as uses of the compounds and the pharmaceutical composition thereof in the preparation of drugs for protecting against, treating, curing or alleviating proliferative diseases of a patient.

Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling

Less is more: A minimalist "clickable" photo-crosslinker (see scheme) was incorporated with numerous small-molecule kinase inhibitors. The resulting probes were used for both in vitro (cell lysates) and in situ (live cells) proteome profiling, for large-scale identification of their potential cellular kinase targets and shows improved outcomes over previous probes. Copyright

AURORA INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Aurora inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

Kinase inhibition and anticancer therapy

This invention relates to novel uses for Compound E in the treatment of diseases, in particular cancer, associated with aberrant kinase expression.

A NOVEL LACTIC ACID FORMULATION OF MK-0457 USEFUL FOR THE TREATMENT OF CANCER

A lactic acid formulation, and a process to prepare that formulation, of MK-0457 is disclosed:. Such a formulation is useful in the treatment of cancer.

ABL KINASE INHIBITION

The present invention relates to inhibition of AbI kinase.

RET TYROSINE KINASE INHIBITION

The present invention provides methods for inhibiting RET tyrosine kinase. Further, the present invention also provides methods of treating or preventing thyroid cancer.